A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

NCT01489943 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

DRUG: GSK1605786 500 mg
DRUG: Midazolam 3 mg
DRUG: Pioglitazone 15 mg
DRUG: Omeprazole 40 mg
DRUG: Rosuvastatin 10 mg

Sponsor

GlaxoSmithKline